StreetInsider.com News Articles

Form 8-K ANAVEX LIFE SCIENCES For: May 20

Fri, 22 May 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260522/26538753.html

Form 8-K ANAVEX LIFE SCIENCES For: May 20

Fri, 22 May 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260522/26538753.html

Anavex receives NASDAQ delinquency notice for late quarterly filing

Fri, 22 May 2026 08:02:02 -0400

Anavex Life Sciences Corp. (NASDAQ: AVXL) received a delinquency notification from Nasdaq on May 20 for failing to file its quarterly report for the period ended March 31, 2026, according to a company statement.

The notification indicates the biopharmaceutical company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its inability to timely file its Form 10-Q quarterly report. The company has until July 20, 2026, to submit a plan to regain compliance with the exchange's listing requirements.

Anavex stated it is working to complete and file the Form 10-Q and submit a compliance plan to Nasdaq. The notification has

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

Fri, 22 May 2026 08:00:00 -0400

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company’s inability to timely file its Form 10-Q for the quarterly period ended March

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

Fri, 22 May 2026 08:00:00 -0400

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

Fri, 22 May 2026 08:00:00 -0400

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

Fri, 22 May 2026 08:00:00 -0400

Form 8-K ANAVEX LIFE SCIENCES For: May 11

Fri, 15 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260515/26505800.html

Form 8-K ANAVEX LIFE SCIENCES For: May 11

Fri, 15 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260515/26505800.html

Form 3 ANAVEX LIFE SCIENCES For: May 04 Filed by: Kellmeyer Terrie

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495190.html

Form 3 ANAVEX LIFE SCIENCES For: May 04 Filed by: Kellmeyer Terrie

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495190.html

Form NT 10-Q ANAVEX LIFE SCIENCES For: Mar 31

Mon, 11 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260511/26469709.html

Form NT 10-Q ANAVEX LIFE SCIENCES For: Mar 31

Mon, 11 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260511/26469709.html

Form 8-K ANAVEX LIFE SCIENCES For: Apr 30

Wed, 06 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260506/26438902.html

Form 8-K ANAVEX LIFE SCIENCES For: Apr 30

Wed, 06 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260506/26438902.html

Anavex names Terrie Kellmeyer interim CEO after Missling departure

Wed, 06 May 2026 07:00:38 -0400

Anavex Life Sciences Corp. (NASDAQ: AVXL) appointed Terrie Kellmeyer as interim chief executive officer following the departure of Christopher Missling from the company on April 30, 2026, according to a company statement.

Kellmeyer previously served as senior vice president of clinical development at the biopharmaceutical company and currently holds the position of senior advisor. The board of directors requested Missling's resignation, the company said.

The new interim CEO brings nearly three decades of pharmaceutical industry experience across drug development, having previously led global regulatory affairs, clinical development, clinical operations, safety, quality assurance and medical affairs departments at multiple healthcare companies. Kellmeyer has

Anavex names Terrie Kellmeyer interim CEO after Missling departure

Wed, 06 May 2026 07:00:38 -0400

Anavex names Terrie Kellmeyer interim CEO after Missling departure

Wed, 06 May 2026 07:00:38 -0400

Anavex names Terrie Kellmeyer interim CEO after Missling departure

Wed, 06 May 2026 07:00:38 -0400

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer